Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Debiopharm Group™ to Collaborate

Published: Wednesday, April 02, 2014
Last Updated: Wednesday, April 02, 2014
Bookmark and Share
Innovative partnership based on Evotec’s Target X projects.

Evotec AG has announced a research collaboration and licensing deal with Debiopharm Group™, Lausanne, Switzerland.

The objective of this collaboration is to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations.

Discovery and pre-clinical development efforts will be driven by Evotec, whilst Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

This program is based on Evotec’s drug discovery efforts to investigate genetically altered targets whose 'driver' role in several cancer types has been validated and on the shared objective of identifying novel therapeutic agents in a variety of cancers, including AML (Acute Myeloid Leukemia), prostate cancer and glioblastoma.

Evotec is in the unique position of being able to apply a broad range of highly sophisticated drug discovery tools including mass spectrometry and structure-based drug design for rapid and efficient development of highly promising lead series.

Debiopharm is experienced in taking to maturity promising early stage biological or small molecule drug candidates from preclinical to clinical development phase I, II and III, including subsequent out-licensing to pharmaceutical partners for sales and marketing.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very excited about this innovative collaboration structure between Debiopharm and Evotec. It combines our proven discovery platform with Debiopharm’s ability to advance projects through clinical development in a highly efficient manner while sharing risks and rewards of Evotec’s TargetX project. There is compelling science around the target and we are confident that we will be able to position highly competitive compounds in this field that hold great potential for difficult to treat cancers.”

"This is a fine example of how drug discovery and development will be in the future: a mixture of complementarities looking to bring to a defined population of patients a drug that will change the outcome of disease" added Andrés McAllister, Chief Scientific Officer, Debiopharm International SA.

“Through this collaboration with Evotec, Debiopharm is strengthening its position in early projects with a leader in the drug discovery field” said Thierry Mauvernay, Delegate of the Board of Debiopharm Group”. Furthermore, this R&D program targeting cancers with known genetic alterations is a whole part of our strategy for personalized medicines”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec AG Reports H1 2013 Results
Company predicts top-line growth in the second half of the year 2013 due to expected milestones.
Friday, August 09, 2013
Scientific News
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!